Timothy Rust, MD
Clinical Neurophysiology · Columbus, OHNPI 1306071899
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,110 of the $8,770 with a category attached, or 81.1%. AstraZeneca accounts for 89.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $6,363 and has fallen 95.0% since, to $317 in 2025.
Across 21 payments — averaging $417.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Argenx US, Inc.$291
- Biogen$225
- SK Life Science, Inc.$194
- UCB, Inc.$125
- Amgen$116
Across 8 payments — averaging $2535.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$20K
What the payments were for
- Speaking & faculty fees$7,11081%
- Travel & lodging$1472%
- Food & beverage$1,48617%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 12 | $7,818 |
| Argenx US, Inc. | 3 | $291 |
| Biogen | 2 | $225 |
| SK Life Science, Inc. | 2 | $194 |
| UCB, Inc. | 1 | $125 |
| Amgen | 1 | $116 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 102 | $17,480 |
| Pyridostigmine Bromide | 91 | $8,447 |
| Gabapentin | 149 | $2,070 |
| Azathioprine | 16 | $1,817 |
| Pregabalin | 65 | $1,704 |
| Memantine Hcl | 24 | $890 |
| Prednisone | 81 | $722 |
| Levetiracetam | 17 | $588 |
| Venlafaxine Hcl | 14 | $559 |
| Nortriptyline Hcl | 55 | $549 |
| Donepezil Hcl | 57 | $523 |
| Amitriptyline Hcl | 41 | $448 |
| Duloxetine Hcl | 18 | $423 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 30 | $396 |
| Primidone | 20 | $280 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Columbus
- Jaclyn LaineColumbus$724
- Adam UeberrothColumbus$109
- John NovakWesterville$113K
- Jennifer DrakeCanton$17K
- Chinasa NwankwoAkron$17K
- Mahmoud MohamedToledo$12K
- Ahmed ArshadToledo$6K
- Andreas AlexopoulosCleveland$2K
- Abuhuziefa AbubakrDayton$902
- Khaled YassineToledo$778
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.